Radiation oncology firm Varian Medical Systems has received clearance for its Halcyon system by the China National Medical Product Administration.
The clearance allows the firm to market its cancer treatment system in China.
Halcyon has already received U.S. Food and Drug Administration 510(k) clearance in the U.S. and the CE Mark in Europe, as well as approval in Japan, Brazil, India, and Taiwan since the system's launch in May 2017, according to Varian.
